Loading…
Hosted by Big4Bio · 🇺🇸 US · EN · 56 episodes
Established thought leaders with verified media credentials.
The Big4Bio Podcast shares podcasts that give insight and information about/from biotech and life science leaders and organizations within the Big4Bio regions. Check out our Playlists to hear podcasts by region.
Big4Bio hosts The Big4Bio Podcast, a science show with 56 episodes published.
Trial design, recruitment, and supply chains represent pain points that routinely derail timelines and budgets for sponsors. There are, however, ways that emerging biotechs can get more speed, rigor, and strategic value
Advances in sequencing, the emergence of antisense oligonucleotide therapies, and the advent of induced pluripotent stem cell technology are among the combination of factors that have made bespoke medicines for individua
Immunogenicity testing helps establish the safety of experimental therapies by ensuring drugs don’t trigger a potentially dangerous immune response. While regulators had long relied on a fixed, three-tier immunogenicity
At Charles River Laboratories, scientific advisors and study directors have complementary roles in nonclinical drug development. Scientific advisors bring years of scientific and regulatory experience to program-level st
Biologic drug development increasingly relies on sensitive, human relevant platforms capable of detecting both intended and unintended target engagement well before first in human studies. Charles River Laboratories is l
The journey from discovery to IND is rarely linear. It demands rigorous target validation, continuous regulatory engagement, and the use of translationally relevant models to effectively de risk programs before they adva
Drug metabolism and pharmacokinetics, often referred to as DMPK, is not just a box to check on the way to advancing an experimental therapy into the clinic. In reality, it is an essential part of determining whether a pr
As the biotech industry shows renewed strength with rising stock prices and growing deal values, thousands of biotech industry leaders, investors, and innovators will gather in San Francisco in January for the annual Bio
Charles River Laboratories is leveraging its deep discovery sciences expertise with advanced computational tools to accelerate drug development, improve safety, and reduce animal use. In this episode of our continuing se
Organoids¬—miniaturized, three-dimensional, lab-grown, tissue cultures that mimic organs¬—can be used to improve drug discovery and safety testing by providing more predictive human biology models than traditional 2D cul
As we continue our Big4Bio occasional series on discovery and safety assessment with Charles River Labs, we explore new approach methodologies, or NAMs, and their integration with antibody discovery and development. We s
California research institutes, universities, and biopharmaceutical companies are a critical source of innovation, contributing to the development of approximately a quarter of new drugs that the U.S. Food and Drug Admin
Discovery is a complex and high-risk process in drug development, as researchers strive to identify and advance promising therapeutic candidates. It requires scientific prowess, advanced technologies, and strategic visio
With government funding cuts to research in the United States and an uncertain and erratic policy environment, stability is emerging as a strength Europe is seeking to leverage to attract scientific investment and talent
The IPO market remains unwelcoming to biotechs and venture investors are reticent to back younger companies. In the absence of reliable funding sources, many biotechs are trying to advance their most promising programs w
In 2022, Charles River Laboratories acquired the vivarium operation services provider Explora BioLabs. The acquisition both complemented and expanded the operations of CRADL (Charles River Accelerator and Development Lab
Biotech companies are more prone than most to shareholder lawsuits because single events can often cause sharp and sudden price drops in their shares. While they buy insurance to protect their officers and directors from
With the JPMorgan Healthcare Conference on the horizon, biotech CEOs are wondering whether the new year will bring a more welcoming IPO market. But Gregg Beloff, co-founder and managing director of Danforth Advisors, sai
The recently released update to the International Council for Harmonisation M12 guidelines provides a consistent approach to drug-drug interaction studies across different regulatory agencies. The new guidelines replace
Partnering has long been a critical engine to drive companies’ success in the life sciences. In the current difficult financing environment, executives and business development leaders need to take advantage of opportuni
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
The Big4Bio Podcast has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
The Big4Bio Podcast is hosted by Big4Bio. The show is categorised under science and has published 56 episodes.
The Big4Bio Podcast has published 56 episodes.
The Big4Bio Podcast regularly covers science. It sits in the science category.
The Big4Bio Podcast is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The Big4Bio Podcast hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The Big4Bio Podcast average 30 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates The Big4Bio Podcast's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 5 days ago.